Beiersdorf Just Bet Big on Your Skin's Microbiome — Here's What That Means
2 September 2026 10 min read 362 views 0
Eucerin's new DERMOPURE CLINICAL PROBIOM8 line uses dormant skin-native bacteria to treat acne-prone skin, rather than sterilising it.
Key takeaways
- Beiersdorf launched Eucerin DERMOPURE CLINICAL PROBIOM8 on 1 September 2026, built around a patented active called TopiC.A.
- The line uses two viable, dormant strains of skin-native bacteria that activate on skin to support a balanced microbiome.
- Beiersdorf's microbiome research dates back to the 1990s, with over 120 proprietary studies conducted since 2014.
- The global acne-prone skin market reached an estimated 4.6 billion euros in 2025, with prevalence highest among 16 to 24-year-olds.
- South Africa's UV exposure, humidity swings and hard water all add extra stress to the skin barrier and microbiome.
From the Knowledge Hub
Sign in to read this briefing
Free accounts get 3 full briefings every week, no card required. Members get unlimited daily briefings.
See membership plansComments (0)
Sign in to join the conversation.
